Precision Chroma

Cover Block

Open sources

Field	Value
Name	Precision Chroma
Tagline	Developing 3D-printed chromatography columns for purifying biologics to reduce manufacturing time and cost. [Precision Chroma, August 2023]
Headquarters	Christchurch, New Zealand [Precision Chroma, August 2023]
Founded	2022 [LinkedIn, retrieved 2026]
Stage	Seed [Crunchbase]
Business Model	B2B
Industry	Deeptech
Technology	Biotech / Life Sciences
Geography	Oceania
Growth Profile	Venture Scale
Founding Team	Academic Spinout [University of Canterbury]
Funding Label	Seed
Total Disclosed Funding	~$7,300,000 [NZ Herald, October 2026]

Links

Open sources

• Website: https://precision-chroma.com/about-us

What an Investor Needs First

PUBLIC Precision Chroma is a University of Canterbury spinout building 3D-printed chromatography columns for biologics purification, a part of biomanufacturing where faster throughput and lower processing cost can matter if the underlying performance claims hold up in customer validation [University of Canterbury] [Bridgewest Ventures] [Precision Chroma]. The company merits attention now because it has moved from university-originated IP into a better-capitalised seed phase, with M Ventures reported as lead investor in a US$7.3 million round announced in October 2026, alongside earlier backing from Bridgewest Ventures, Icehouse Ventures, and New Zealand Growth Capital Partners [NZ Herald, October 2026] [Scoop, August 2023].

The founding story is relatively clear in public materials. Sean Feast founded the company in 2022, after completing a PhD at the University of Canterbury on the same chromatography technology, while Professor Conan Fee is identified as the original inventor and an academic collaborator and mentor tied to the underlying research base [University of Canterbury] [LinkedIn] [Precision Chroma].

The core product is a patented Printed Monolith Adsorption, or PMA, chromatography system, described as a 3D-printed porous-media column designed to separate and purify biological molecules from fluid mixtures for applications including vaccines, gene therapies, plasmid purification, and broader biologics manufacturing [University of Canterbury] [Bridgewest Ventures] [B2B News]. The differentiation, according to company and partner materials, rests on flow characteristics and process efficiency rather than on a novel end market, with Precision Chroma stating that sample release for its ProA Complete Capture Columns is expected in late 2026 and that an early access program opens in late 2025 [Precision Chroma].

Team-market fit is strongest on the technical side. Feast's public record shows formal training in chemical and process engineering, and the company remains closely linked to the University of Canterbury research effort that produced the technology; what is less established in public evidence is commercial scale-up at volume, which makes third-party validation and early customer uptake the key proof points to watch [University of Canterbury] [Precision Chroma].

The business model is B2B, aimed at pharmaceutical manufacturers and CDMOs, and the financing history is directionally positive but somewhat messy in public databases. Precision Chroma announced a NZ$1.5 million raise in August 2023, while Crunchbase lists a 2022 seed financing of $5.38 million and later coverage describes the 2026 round as seed as well, so stage labels and cumulative totals should be read with some care until cap table materials are reviewed directly [Precision Chroma, August 2023] [Crunchbase] [NZ Herald, October 2026].

Over the next 12 to 18 months, the public milestones that matter are product sampling, evidence from validation work, and signs that the company can translate academic and investor support into repeatable adoption inside regulated bioprocessing workflows [Precision Chroma] [NZ Herald, October 2026]. That is the right frame for this company: the technical premise is interesting and the sponsor set is credible, but the investment case still turns on external proof that PMA columns outperform incumbent purification approaches in real manufacturing settings [Bridgewest Ventures] [Precision Chroma].

Partially corroborated -- Mix of independent coverage, university materials, investor announcements, and company disclosures; several forward-looking product milestones remain company-only.

Taxonomy Snapshot

Axis	Value
Stage	Seed
Business Model	B2B
Industry / Vertical	Deeptech
Technology Type	Biotech / Life Sciences
Geography	Oceania
Growth Profile	Venture Scale
Founding Team	Academic Spinout
Funding	Disclosed seed funding of approximately $7.3 million [NZ Herald, October 2026]

Inside the Company

PUBLIC

Precision Chroma presents as a University of Canterbury spinout built around one fairly specific manufacturing bottleneck: purification in biologics production. The company is headquartered in Christchurch, New Zealand, and was founded in 2022, according to Crunchbase and public company materials [Crunchbase] [Precision Chroma]. On its website, the company says it is developing 3D-printed chromatography columns intended to reduce the time and cost of purifying biological products, with the underlying technology originating from research at the University of Canterbury [Precision Chroma].

The chronology is still early, but the public record is coherent on the main milestones. Crunchbase records an early financing event on May 6, 2022, for $5,379,633, although the round labeling and lead investor detail are limited in the public profile [Crunchbase]. In August 2023, Precision Chroma announced a $1.5 million raise to support research and development, team growth, and commercial preparation, framing the company as part of Callaghan Innovation's technology incubation pathway [Precision Chroma, August 2023]. The website also indicates that an early access program is expected to open in late 2025, with sample release of ProA Complete Capture Columns expected in late 2026, which helps place the business as pre-commercial rather than in broad market deployment today [Precision Chroma].

Partially corroborated -- Confirmed in part by Crunchbase and the company website, with some milestone details supported only by company materials.

Under the Hood

Under the Hood

MIXED Precision Chroma is building 3D-printed chromatography columns for the purification step in biologics manufacturing, a part of the process that can become slow and expensive when manufacturers are separating proteins, antibodies, nucleic acids, or viral material from fluid mixtures [University of Canterbury] [Bridgewest Ventures]. Public materials describe the company’s core product as patented porous-media columns commercialised from University of Canterbury research, with applications in vaccines, cell and gene therapies, plasmid purification, and broader biologics production [University of Canterbury] [Bridgewest Ventures]. The technical label used in public coverage is Printed Monolith Adsorption, or PMA, which B2B News described as a patented 3D-printed chromatography system intended to speed purification of proteins, antibodies, vaccines, and gene therapies [B2B News].

The company’s public wedge is process speed at scale, but the strongest performance claims still sit mostly on company-controlled channels. Precision Chroma says its PMA columns can operate at high flow rates with unrestricted pressure and process large-scale, solids-laden cell culture products quickly [Precision Chroma]. That is directionally interesting because conventional chromatography often forces a throughput-versus-pressure tradeoff, but the available public evidence here does not include third-party benchmark data, validation protocols, or side-by-side results against incumbent columns. Public materials do, however, establish the intended buyer and workflow position clearly: pharmaceutical manufacturers and CDMOs are the target users, and the product is meant to reduce manufacturing time and cost while improving yield in downstream purification [Bridgewest Ventures] [Scoop, August 2023].

The announced product timeline is early rather than fully commercial. Precision Chroma’s public expression-of-interest page says an early access program will open in late 2025 and that sample release for its ProA Complete Capture Columns is expected in late 2026 [Precision Chroma]. That places the company, on public evidence, in a pre-broad-release phase where the underlying science appears real and institutionally anchored, but commercial proof will depend on whether those columns translate laboratory performance into reproducible manufacturing results under customer validation conditions [University of Canterbury] [Precision Chroma].

Partially corroborated -- Product category and scientific origin are corroborated by University of Canterbury and Bridgewest Ventures, but key performance and release-timing claims rely substantially on company materials.

Market Research

PUBLIC

The market matters now because biologics output keeps expanding while downstream purification remains one of the slower and more expensive steps in manufacturing, which gives process-intensification tools a clear opening if they can be validated in regulated workflows [Bridgewest Ventures] [Precision Chroma, August 2023].

Public evidence on market size is thin, and that matters for how aggressively to read the opportunity. The only explicit sizing claim in the source set is the company statement that bio-separations is an "$8.5 billion market" [Precision Chroma, August 2023]. That figure is useful as a directional signal, but it is company-supplied rather than independently benchmarked, so it should not be treated as a fully corroborated TAM. More defensibly, the product sits inside the broader bioprocessing and biologics manufacturing stack, specifically downstream purification for molecules such as proteins, antibodies, vaccines, and gene-therapy related products, all of which are named in public descriptions of the technology and its intended use cases [B2B News] [Bridgewest Ventures].

The immediate demand driver is straightforward: if a column architecture can process more material at higher flow rates and with fewer purification steps, it addresses a pain point that pharmaceutical manufacturers and CDMOs already budget around [Bridgewest Ventures] [Precision Chroma]. Precision Chroma's public materials position its Printed Monolith Adsorption system around faster purification of proteins, antibodies, vaccines, and gene therapies, while Bridgewest's coverage frames the buyer set as scaled biologics producers rather than research-only users [B2B News] [Bridgewest Ventures]. That places the company's practical near-term market closer to manufacturing process development and production operations than to the full analytical chromatography universe.

Adjacent markets widen the strategic scope, but they also complicate adoption. Precision Chroma's materials point to applications in plasmid purification, cell and gene therapies, and vaccine production, which suggests adjacency to nucleic-acid manufacturing and viral-vector processing as well as conventional monoclonal antibody purification [Bridgewest Ventures]. Those are attractive end markets because they tend to tolerate high-value process improvements, but each comes with different validation requirements, feedstream characteristics, and incumbent workflows. In other words, the platform narrative is broader than any one product line, yet commercial entry will likely remain application-specific until external validation is clearer [Precision Chroma] [Bridgewest Ventures].

Regulatory and macro forces cut both ways. On the positive side, biomanufacturing resilience has become a policy topic in several markets, and Precision Chroma's public ecosystem includes university IP, New Zealand incubation support, and reported later-stage backing from M Ventures and New Zealand Growth Capital Partners, which indicates institutional interest in production-enabling infrastructure rather than consumer-facing biotech narratives [University of Canterbury] [NZ Herald, October 2026]. The constraint is that downstream purification equipment does not win on novelty alone. In regulated biologics production, any claimed gains in speed, yield, or solids handling still need to fit qualification, comparability, and customer process-transfer requirements, which tends to slow market conversion even when the technical proposition is strong [Bridgewest Ventures] [Precision Chroma].

Sizing claim	Figure	Scope	Source
Bio-separations market	$8.5B	Company-stated market size for the category	[Precision Chroma, August 2023]

The table is intentionally sparse because the public record here is sparse. For investors, that shifts the market question from headline TAM to whether the company can wedge into a high-value purification bottleneck within biologics manufacturing and then expand across adjacent molecule classes.

Claim stands unchecked -- This section relies materially on one company-stated market sizing claim, with adjacent market framing corroborated by company and investor materials rather than independent third-party market reports.

Competition and Substitutes

Market structure

MIXED Precision Chroma appears to be competing less against a single named startup peer and more against the established process stack that biopharma manufacturers already use for downstream purification, with its positioning centered on replacing slower or more constrained chromatography steps through a 3D-printed column architecture called Printed Monolith Adsorption, or PMA [B2B News] [Bridgewest Ventures].

The public record is thin on named direct competitors, and that matters in itself. Available sources name the company, its academic origin, and its investors, but do not identify a specific rival set, which suggests the company is still selling a technical shift into a market where buyer reference points are likely incumbent purification workflows rather than a crowded startup category [University of Canterbury] [Precision Chroma]. In practice, the comparison set is likely to include existing chromatography columns and purification processes already used by pharmaceutical manufacturers and CDMOs, because Precision Chroma says its columns are designed to separate and purify biological molecules for vaccines, cell and gene therapies, plasmid purification, and broader biologics manufacturing [Bridgewest Ventures].

A useful way to map the field is by segment rather than by logo. Incumbents are the entrenched purification methods already qualified inside biologics plants, where switching costs are typically operational and regulatory as much as commercial, based on Precision Chroma's stated application areas in biologics manufacturing [Bridgewest Ventures]. Challengers are newer platform suppliers trying to improve throughput or yield in bioprocessing, though the provided sources do not name them. Adjacent substitutes are service providers and CDMOs that can absorb process complexity on behalf of customers rather than asking them to adopt a new core component, a category that matters because Precision Chroma explicitly targets pharmaceutical manufacturers and CDMOs as buyers [Bridgewest Ventures] [Scoop, August 2023].

The company's edge today looks strongest in origin and technical specificity, but weaker in proven market access. The underlying technology came out of the University of Canterbury, with Professor Conan Fee identified as the original inventor and Sean Feast's PhD tied to the same technology, which gives Precision Chroma a credible scientific lineage and a clearer claim to differentiated know-how than many early industrial spinouts can show [University of Canterbury]. The durability of that edge depends on whether the patented PMA system translates into validated performance under commercial conditions, because the strongest public performance claims, such as high flow rates and unrestricted pressure for large-scale solids-laden products, still rest on company materials rather than independent third-party validation [Precision Chroma].

Distribution is where the advantage is more conditional. Bridgewest Ventures has been involved since the commercialisation stage, and the company later added M Ventures, Icehouse Ventures, and New Zealand Growth Capital Partners to the investor base, which could widen industrial access and scientific credibility over time [Bridgewest Ventures] [NZ Herald, October 2026]. Still, investors do not by themselves solve adoption risk. Precision Chroma's own timeline points to an early access program in late 2025 and sample release for ProA Complete Capture Columns in late 2026, which indicates that broad commercial proof remains ahead rather than behind the company [Precision Chroma].

The main exposure is not that a named startup has already outflanked it in the supplied record, but that incumbent process qualification and buyer conservatism can be a stronger competitive force than any venture-backed rival. A purification component used in vaccines, antibodies, or gene therapy manufacturing has to earn trust inside highly controlled production environments, and public evidence here does not yet show commercial deployments at scale [Bridgewest Ventures] [Precision Chroma]. That leaves Precision Chroma exposed to better-capitalized incumbent suppliers and to CDMOs that can package existing methods into a lower-friction offering, even if the startup's underlying science is attractive.

Over the next 18 months, the most plausible competitive scenario is a bifurcation between technical validation and commercial standard-setting. Precision Chroma is the most obvious winner if its late-stage product milestones convert into independent validation with large biopharma or CDMO users, because that would turn its academic and patent position into a real switching argument [Precision Chroma] [University of Canterbury]. Precision Chroma is also the most likely loser if those milestones slip or remain supported mainly by company claims, because in that case the default winner is the incumbent purification stack already embedded in customer facilities, which benefits from qualification, familiarity, and procurement inertia rather than superior novelty [Bridgewest Ventures] [Precision Chroma].

Opportunity

PUBLIC The prize here is not a modest process improvement, it is a chance to become a new hardware-and-consumables layer inside biologics manufacturing, a category where even one accepted purification step can sit close to the production line for years [Bridgewest Ventures] [University of Canterbury] [Precision Chroma, August 2023].

The headline opportunity is straightforward: if Precision Chroma can show that its 3D-printed Printed Monolith Adsorption columns materially reduce purification time and cost while maintaining yield at commercial scale, it could become a meaningful supplier to pharmaceutical manufacturers and CDMOs across biologics workflows [Bridgewest Ventures] [B2B News] [Precision Chroma]. That outcome is reachable, rather than purely aspirational, because the company is not proposing an abstract software layer. It is commercialising university-originated intellectual property, tied to a defined bottleneck in bioprocessing, with backing from specialist investors and a stated path toward product samples and early access [University of Canterbury] [Precision Chroma, August 2023] [Precision Chroma]. The evidence base is still early and partly company-led, but the combination of a patented process technology, an academic origin, and seed financing from investors with life sciences exposure gives the opportunity a tangible operating path [University of Canterbury] [NZ Herald, October 2026].

The most credible upside paths are less about broad horizontal expansion at once and more about winning one manufacturing use case, then extending from there.

Scenario	What happens	Catalyst	Why it's plausible
Capture-step wedge	Precision Chroma's ProA Complete Capture Columns win adoption in antibody purification, initially through pilot and validation work, then expand into repeat purchasing by manufacturers and CDMOs.	Sample release in late 2026 and the earlier access program create a concrete conversion point from technical interest to process trials [Precision Chroma].	The company has named a specific product surface, ProA Complete Capture Columns, and positions it around high-value biologics purification where chromatography is already a core step [Precision Chroma] [Bridgewest Ventures].
CDMO distribution path	The company becomes an embedded tool supplier to contract manufacturers that run purification on behalf of multiple drug programs, giving one commercial relationship exposure to many end customers.	Relationships built through Bridgewest's biomanufacturing network, including BioCina, help move the technology from development into scaled manufacturing settings [Bridgewest Ventures].	Public materials already frame pharmaceutical manufacturers and CDMOs as target buyers, and Bridgewest has described BioCina as a scaling partner for development work [Bridgewest Ventures] [Scoop, August 2023].
Platform expansion beyond one modality	A first accepted product in protein purification broadens into adjacent applications such as vaccines, plasmids, and cell and gene therapy workflows, turning one column architecture into a family of process products.	Successful validation in one modality creates technical credibility for adjacent molecule classes and process steps [Bridgewest Ventures] [B2B News].	Public descriptions already position the underlying platform across vaccines, cell and gene therapies, plasmid purification, and biologics manufacturing rather than a single narrow use case [Bridgewest Ventures] [B2B News].

The compounding mechanism, if it appears, would likely come from process qualification and repeat consumables demand rather than from a conventional software network effect. Once a biologics manufacturer validates a purification component inside a regulated process, switching costs can become operationally high because any process change may require fresh technical work and internal approval. Precision Chroma's public materials suggest the first loop: university-developed IP feeds product development, specialist investors fund scale-up, and early access plus sample release are meant to pull prospective users into trials that can turn into long-duration supply relationships [University of Canterbury] [Precision Chroma] [Precision Chroma, August 2023]. If that loop works, each successful installation could support three forms of compounding: proof for the next buyer, application expansion into adjacent biologic classes, and recurring demand for replacement or expanded column volumes.

The size of the win is still better framed through category economics than through direct public comparables, because no named competitor set was confirmed in the source pack. Precision Chroma itself cites the bio-separations market at $8.5 billion, although that figure is company-provided and not independently corroborated in the available public record [Precision Chroma, 2023]. Even using that cautiously, a company that became a trusted supplier in a small but important slice of biologics purification could support a substantial outcome. For example, if Precision Chroma ultimately captured 1 percent of an $8.5 billion market, that would imply about $85 million in annual revenue (scenario, not a forecast), and a differentiated life sciences tools business at that scale could plausibly support venture-level value creation if gross margins and repeat usage proved attractive. That remains conditional on technical validation, commercial adoption, and manufacturability, but the upside case is concrete enough to matter.

Claim stands unchecked -- This section relies materially on company and investor materials for product scope, market framing, and commercial timeline, with partial corroboration from University of Canterbury, Scoop, and NZ Herald.

Sources

Open sources

1. [Precision Chroma, August 2023] Scaling Up: Precision Chroma’s $1.5M Raise to Accelerate Global Reach | https://precision-chroma.com/news/scaling-up-precision-chromas-15m-raise-to-accelerate-global-reach

2. [LinkedIn, retrieved 2026] Sean Feast - Founder/CEO - Precision Chromatography Limited | LinkedIn | https://www.linkedin.com/in/sean-feast-170ba0183/

3. [Crunchbase] Precision Chroma - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/precision-chroma

4. [University of Canterbury] Sean Feast | https://www.canterbury.ac.nz/about-uc/why-uc/our-alumni/young-alumni/sean-feast

5. [NZ Herald, October 2026] Merck leads $13m raise for Christchurch start-up Precision Chroma | https://www.nzherald.co.nz/business/merck-leads-13m-raise-for-christchurch-start-up-precision-chroma/premium/K3E725YPRJF3BGWERWCRUC6K4I/

6. [Bridgewest Ventures] Dr Sean Feast on revolutionising the biological separations industry | https://bridgewest.ventures/news-events/dr-sean-feast-on-revolutionising-the-biological-separations-industry

7. [Precision Chroma] About Us | https://precision-chroma.com/about-us

8. [B2B News] Precision Chroma: Breaking the Mold with 3D-Printed Chromatography | https://www.analyticalchemistrystartups.com/post/breaking-the-mold-with-3d-printed-chromatography

9. [Scoop, August 2023] Biotech startup Precision Chroma to access global markets after latest raise.htm | https://www.scoop.co.nz/stories/SC2308/S00015/biotech-startup-precision-chroma-to-access-global-markets-after-latest-raise.htm